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Antiplatelet agents such as aspirin, clopidogrel, and di-pyridamole are effective in secondary stroke prevention
with single agents reducing risk by 15% to 20%1–3; the
addition of a second agent (eg, combining aspirin and
dipyridamole) doubles this benefit.3 As with other vascular
prevention strategies, eg lowering blood pressure and choles-
terol, antiplatelet agents reduce, not abolish, risk. Despite
this, the concept of “aspirin failure” (ie, where a further event
occurs despite aspirin) is discussed widely; this contrasts with
other prophylactic strategies in which events occurring on
antihypertensive or lipid-lowering therapy are not described
as failures. In parallel, another concept, resistance to anti-
platelet agents (eg, “aspirin resistance,” “clopidogrel resis-
tance”) has come to the forefront4; here, some patients may be
less sensitive to an antiplatelet agent than other patients. Such
variation in response is widely recognized and accounted for
in guidelines5 for other vascular prophylactic strategies such
as antihypertensive agents; for example, younger patients are
more sensitive to angiotensin-converting enzyme inhibitors
than older subjects with the reverse being true for calcium
channel blockers and diuretics.
The concepts of “antiplatelet failure” and “antiplatelet
resistance” have led to the question of whether measuring the
functional activity of antiplatelet agents might predict re-
sponse to treatment and efficacy in vascular prevention.
When using antihypertensive agents, we know that lowering
blood pressure acts as a reliable surrogate for the resulting
reduction in stroke and myocardial infarction.6 However,
unlike blood pressure, there is no global measure of platelet
function, although cutaneous bleeding time7 has been pro-
posed; unfortunately, it does not assess platelet function in
high-pressure/high-shear conditions, is influenced by non-
platelet factors (such as hematocrit), and is very dependent on
both operator and measurement environment. Similarly,
platelet size, a determinant of platelet function and predictor
of recurrent stroke events,8 does not appear to be satisfactory
because antiplatelet agents such as aspirin do not alter it.
In the absence of a suitable global measure of platelet
function, interest is growing in assessing specific aspects of
platelet function, in particular those relevant to the antiplate-
let agent being used. So, response to aspirin might be
assessed using platelet aggregation after stimulation with
arachidonic acid or assay of thromboxane metabolites (eg,
urinary thromboxane B2). Similarly, sensitivity to clopidogrel
can be assessed using platelet aggregation in response to
adenosine 5-diphosphate. It is more problematic to measure
the effects of dipyridamole because it is a stimulator of
endogenous platelet inhibitory systems, whereas most mea-
sures of platelet function rely on activating them. However,
these measures do not replicate the environment that platelets
see in the arterial tree. To overcome this, a number of
semiautomatic cartridge-based systems have been developed
that create shear by forcing blood over a platelet-activating
surface, eg, containing collagen and either adenosine 5-
diphosphate or epinephrine (as used in the PFA-100 system).
If specific measures of platelet function were strongly
related to subsequent stroke and other vascular events, their
use might be warranted. However, such evidence is lacking
and the evidence that so-called aspirin- or clopidogrel-resis-
tant people are more likely to go on to have a clinical event
is weak. Furthermore, the tests are expensive both financially
and in time.
By analogy with hypertension, using specific assessments
of platelet function is akin to measuring blood norepinephrine
or renin levels rather than blood pressure. What we really
need for monitoring the effects of antiplatelet agents is a
global measure of platelet function. Until such a measure can
be identified, the routine measurement of platelet function
using specific assessments such as aggregation or shear-based
systems cannot be recommended. Clearly, the use of these
approaches in research remains valid, both to address the
issues raised here and to support and continue the search for
a true global measure. In the meantime, if events occur on
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monotherapy, add rather than substitute another antiplatelet
as is done with antihypertensive agents.
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